Cutaneous T-Cell Lymphoma Diagnosis Market Set to Surpass US$ 425.8 Million by 2034, States Fact.MR Rockville, MD, Dec. 12, 2024 (GLOBE NEWSWIRE) -- According to Fact.MR, a market research and competitive intelligence provider, the global Cutaneous T-cell lymphoma diagnosis market is estimated to...

萬聯行在香港獲得Targretin®️（Bexarotene）用於皮膚T細胞淋巴瘤的上市批准 香港和澳門的獲批為Targretin®️首次在中國區域內上市Bexarotene為國際臨床慣例用於治療復發性皮膚T細胞淋巴瘤(CTCL)的標準藥物 香港, July 16, 2024 (GLOBE NEWSWIRE) --...

万联行获得Targretin®（Bexarotene 贝沙罗汀）在香港用于皮肤T细胞淋巴瘤的市场批准 香港和澳门的批准标志着Targretin®首次在中国上市贝沙罗汀代表国际临床实践中对复发性皮肤T细胞淋巴瘤(CTCL)的标准治疗 香港, July 16, 2024 (GLOBE NEWSWIRE) -- 万联行有限公司（“Main Life”）今天宣布Targretin®（贝沙罗汀）胶囊在香港获得上市许可，用于治疗至少一次系统治疗无效的皮肤T细胞淋巴瘤 （Cutaneous T-cell...

Main Life received Targretin® (Bexarotene) Marketing Authorisation in Hong Kong for Cutaneous T-Cell Lymphoma Targretin® (Bexarotene) received Marketing Authorisation in Hong Kong for Cutaneous T-Cell Lymphoma.

Global Cutaneous T-cell Lymphoma Market is projected to be worth USD 3531.5 Million by 2030 I SPER Market Research New York, Nov. 30, 2021 (GLOBE NEWSWIRE) -- The global cutaneous T-cell Lymphoma market is expected to grow at a CAGR of 8.56% from 2020 to reach USD 3531.5 billion by 2030. The growth is primarily...